October 27-30, 2026 | Hamburg, Germany | Booth #TBD

StageBio is heading to ESGCT 2026, the 33rd Annual Congress of the European Society of Gene and Cell Therapy, taking place at the Congress Center Hamburg from October 27–30.

The ESGCT Annual Congress brings together researchers, biotechnology and pharmaceutical companies, clinicians, and industry partners working across gene therapy, cell therapy, gene editing and advanced therapeutic modalities. The meeting provides a platform for sharing the latest developments in areas including viral and non-viral vectors, CAR-T and other engineered cell therapies, gene editing, RNA therapeutics and translational development. 

Visit StageBio at Booth #TBD to meet our team and discuss how specialised histopathology, molecular pathology and tissue-based analysis can support your gene and cell therapy programme from early research through preclinical and regulatory development.

Supporting Gene & Cell Therapy Development Through Tissue Evaluation

Understanding where a therapy goes, what it expresses and how tissues respond can be critical when evaluating novel gene and cell therapies.

StageBio supports sponsors with tissue-based approaches designed around the biology, modality and development stage of each programme, including:

• Histology and histopathology | evaluation of tissue response, inflammation, toxicity and treatment-related findings

• Immunohistochemistry (IHC) and immunofluorescence (IF) | localisation and quantification of transgene products, therapeutic cells, immune populations and relevant biomarkers

• In situ hybridisation (ISH) | tissue localisation of relevant nucleic acid targets and transgene expression

• Digital pathology and image analysis | quantitative assessment of cell populations, biomarker expression and tissue changes

• Specialist pathology review | interpretation by experienced veterinary and toxicologic pathologists

• Good Laboratory Practice (GLP) and non-GLP support | from exploratory research through regulatory-focused preclinical studies

Whether your programme involves adeno-associated virus (AAV), lentiviral vectors, gene editing, engineered cell therapies, CAR-T, RNA-based approaches or other advanced modalities, our team can help define the right tissue evaluation strategy for your development programme.

Meet Our Team

Ayse Müller Managing Director, StageBio Germany Ayse combines scientific and operational leadership with a strong focus on long-term client partnerships. Based at StageBio's Freiburg facility, she works closely with biotechnology and pharmaceutical sponsors to ensure complex histopathology programmes are delivered efficiently, transparently and to the quality standards required for drug development.

Garek Wilashko  Business Development Director Garek works with biotechnology, pharmaceutical and CRO partners across Europe to understand their preclinical tissue evaluation requirements and connect programmes with the appropriate StageBio scientific expertise. His focus is on helping sponsors plan studies early, identify the right pathology and biomarker approaches, and build efficient outsourcing strategies around upcoming development milestones.

Let's Talk About Your Programme

Heading to Hamburg for ESGCT 2026?

Visit StageBio at Booth #TBD to discuss how our histopathology, molecular pathology and digital pathology capabilities could support your gene or cell therapy programme.

Whether you are planning an exploratory tissue study, developing a new biomarker assay, evaluating tissue localisation or preparing for an IND/CTA-enabling programme, our team will be available to talk through your study requirements.

Schedule a meeting with StageBio at ESGCT 2026